| Literature DB >> 34168368 |
Alon Wellner1, Conor McMahon2,3, Morgan S A Gilman2, Jonathan R Clements1, Sarah Clark4, Kianna M Nguyen1, Ming H Ho1, Vincent J Hu1, Jung-Eun Shin5, Jared Feldman6, Blake M Hauser6, Timothy M Caradonna6, Laura M Wingler7,8,9, Aaron G Schmidt4,6, Debora S Marks5,10, Jonathan Abraham4,10,11, Andrew C Kruse12, Chang C Liu13,14,15.
Abstract
The predominant approach for antibody generation remains animal immunization, which can yield exceptionally selective and potent antibody clones owing to the powerful evolutionary process of somatic hypermutation. However, animal immunization is inherently slow, not always accessible and poorly compatible with many antigens. Here, we describe 'autonomous hypermutation yeast surface display' (AHEAD), a synthetic recombinant antibody generation technology that imitates somatic hypermutation inside engineered yeast. By encoding antibody fragments on an error-prone orthogonal DNA replication system, surface-displayed antibody repertoires continuously mutate through simple cycles of yeast culturing and enrichment for antigen binding to produce high-affinity clones in as little as two weeks. We applied AHEAD to generate potent nanobodies against the SARS-CoV-2 S glycoprotein, a G-protein-coupled receptor and other targets, offering a template for streamlined antibody generation at large.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34168368 PMCID: PMC8463502 DOI: 10.1038/s41589-021-00832-4
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 16.174